Ruvonoflast

Ruvonoflast
Clinical data
Other names	NT-0796
Identifiers
	IUPAC name propan-2-yl (2R)-2-(1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyloxy)-3-pyrimidin-2-ylpropanoate;
CAS Number	2272917-13-0;
PubChem CID	152031485;
ChemSpider	129309203;
UNII	S7V5RX5WBZ;
ChEMBL	ChEMBL5409389;
Chemical and physical data
Formula	C23H27N3O4
Molar mass	409.486 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)OC(=O)[C@@H](CC1=NC=CC=N1)OC(=O)NC2=C3CCCC3=CC4=C2CCC4;
	InChI InChI=InChI=1S/C23H27N3O4/c1-14(2)29-22(27)19(13-20-24-10-5-11-25-20)30-23(28)26-21-17-8-3-6-15(17)12-16-7-4-9-18(16)21/h5,10-12,14,19H,3-4,6-9,13H2,1-2H3,(H,26,28)/t19-/m1/s1; Key:UMUQEMHROZVOTF-LJQANCHMSA-N;

Ruvonoflast is an investigational new drug that is being evaluated by Nodthera for the treatment of obesity in patients with high cardiovascular risk. It is an NLRP3 inflammasome inhibitor.^[1]^[2]

References

↑ "NT 0796". AdisInsight. Springer Nature Switzerland AG.
↑ Ray KK, Clarke N, Thornton P, Miles AE, Digby Z, Davies MJ, et al. (May 2026). "Anti-Inflammatory Effects of Oral NLRP3 Inhibition With Ruvonoflast Among Individuals at Elevated Cardiovascular Risk". Journal of the American College of Cardiology: S0735–1097(26)06570–8. doi:10.1016/j.jacc.2026.05.014. PMID 42187339.